Pharmacotherapy for Obesity: Past, Present and Future

Journal of Experimental and Clinical Medicine

Volumn 2, Issue 3, 2010, Pages 118-123

  Hsu, Ya Wen ^a,e   Chu, Da Chen ^b   Ku, Po Wen ^c,e   Liou, Tsan Hon ^a,d   Chou, Pesus ^e  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c NATIONAL CHANGHUA UNIVERSITY OF EDUCATION   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Orlistat; Overweight; Rimonabant; Sibutramine

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; GHRELIN RECEPTOR; GHRELIN RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; LORCASERIN; OTENABANT; PLACEBO; RIMONABANT; SEROTONIN 2C AGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

ANXIETY; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CLINICAL TRIAL; CONSTIPATION; DEFECATION URGENCY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; ENERGY EXPENDITURE; EXERCISE; FATTY ACID STOOL; FECES INCONTINENCE; GASTROINTESTINAL DISEASE; HEART PALPITATION; HEART RATE; HUMAN; INSOMNIA; LIFESTYLE MODIFICATION; LOOSE FECES; MALABSORPTION; MORBIDITY; MORTALITY; OBESITY; OILY SPOTTING; OILY STOOL; PRACTICE GUIDELINE; PREVALENCE; PULSE RATE; QT PROLONGATION; REVIEW; SIDE EFFECT; SPOTTING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THERMOGENESIS; VASOCONSTRICTION; WAIST CIRCUMFERENCE; XEROSTOMIA;

EID: 77953891130     PISSN: 18783317     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1878-3317(10)60019-8     Document Type: Review

References (43)

1. Padwal RS, Majumdar SR Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007, 369:71-77.
2. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113:898-918.
3. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. Obes Res 1998, 6(Suppl 2):51S-209S.
4. Expert Panel on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998, 158:1855-1867.
5. Khan LK, Serdula MK, Bowman BA, Williamson DF Use of prescription weight loss pills among U.S. adults in 1996-1998. Ann Intern Med 2001, 134:282-286.
6. Schwizer W, Asal K, Kreiss C, Mettraux C, Borovicka J, Remy B, Guzelhan C, et al. Role of lipase in the regulation of upper gastrointestinal function in humans. Am J Physiol 1997, 273:G612-G620.
7. Stafford RS, Radley DC National trends in antiobesity medication use. Arch Intern Med 2003, 163:1046-1050.
8. Blanck HM, Khan LK, Serdula MK Use of nonprescription weight loss products-results from a multistate survey. JAMA 2001, 286:930-935.
9. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS Valvular heart disease associated with fenfluraminephentermine. N Engl J Med 1997, 337:581-588.
10. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Heath and Human Services interim public health recommendations, November 1997. Morb Mortal Wkly Rep 1997, 46:1061-1066.
11. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000, 343:1826-1832.
12. Morgenstern LB, Viscoli CM, Kernan WN, Brass LM, Broderick JP, Feldmann E, Wilterdink JL, et al. Use of ephedra-containing products and risk for hemorrhagic stroke. Neurology 2003, 60:132-135.
13. Gura T Obesity drug pipeline not so fat. Science 2003, 299:849-852.
14. Vincent RP, le Roux CW New agents in development for the management of obesity. Int J Clin Pract 2007, 61:2103-2112.
15. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998, 352:167-172.
16. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155-161.
17. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005, 142:532-546.
18. Richelsen B, Tonstad S, Rossner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 2007, 30:27-32.
19. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999, 281:235-242.
20. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005, 293:2873-2883.
21. Maahs D, de Serna DG, Kolotkin RL, Ralston S, Sandate J, Qualls C, Schade DS Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006, 12:18-28.
22. McNeely W, Benfield P Orlistat. Drugs 1998, 56:241-250.
23. Garcia SB, Barros LT, Turatti A, Martinello F, Modiano P, Ribeiro-Silva A, Vespucio MV, et al. The anti-obesity agent orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett 2006, 240:221-224.
24. Singh A, Sarkar SR, Gaber LW, Perazella MA Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007, 49:153-157.
25. Halford JC, Cooper GD, Dovey TM The pharmacology of human appetite expression. Curr Drug Targets 2004, 5:221-240.
26. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000, 356:2119-2125.
27. Arterburn DE, Crane PK, Veenstra DL The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004, 164:994-1003.
28. Padwal R, Li SK, Lau DC Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004, CD004094.
29. Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, Perry AC, Sothern MS, et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006, 145:81-90.
30. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003, 289:1805-1812.
31. Luque CA, Rey JA Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 1999, 33:968-978.
32. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007, 28:2915-2923.
33. Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, et al. Blood pressure changes associated with sibutramine and weight management-an analysis from the 6-week lead-in period of the Sibutramine Cardiovascular Outcomes Trial (SCOUT). Diabetes Obes Metab 2009, 11:239-250.
34. Ernest D, Gershenzon A, Corallo CE, Nagappan R Sibutramine-associated QT interval prolongation and cardiac arrest. Ann Pharmacother 2008, 42:1514-1517.
35. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity 2009, 17:494-503.
36. Ahima RS, Osei SY Leptin signaling. Physiol Behav 2004, 81:223-241.
37. Masuzaki H, Tanaka T, Ebihara K, Hosoda K, Nakao K Hypothalamic melanocortin signaling and leptin resistance-perspective of therapeutic application for obesity-diabetes syndrome. Peptides 2009, 30:1383-1386.
38. van Thuijl H, Kola B, Korbonits M Appetite and metabolic effects of ghrelin and cannabinoids: involvement of AMP-activated protein kinase. Vitam Horm 2008, 77:121-148.
39. Ashby DR, Ford HE, Wynne KJ, Wren AM, Murphy KG, Busbridge M, Brown EA, et al. Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int 2009, 76:199-206.
40. Massolt ET, van Haard PM, Rehfeld JF, Posthuma EF, van der Veer E, Schweitzer DH Appetite suppression through smelling of dark chocolate correlates with changes in ghrelin in young women. Regul Pept 2010, 161:81-86.
41. Nagy TR, Blaylock ML, Garvey WT Role of UCP2 and UCP3 in nutrition and obesity. Nutrition 2004, 20:139-144.
42. Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, Koda JE, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmaco-therapy. Obesity 2009, 17:1736-1743.
43. Kopelman P, Groot Gde H, Rissanen A, Rossner S, Toubro S, Palmer R, Hallam R, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity 2010, 18:108-115.